Chiesi USA, Inc.
$30.8M 9,915 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Novo Nordisk Inc
Novo Nordisk Inc reported $30,880,705.67 across General Payments, Research, and Ownership to 495,369 physicians and teaching hospitals across 497,147 transactions.
- $30.9M Top 10% payer
- All-tracks total
- 497,147 Top 1% volume
- Transactions
- 495,369 Top 1% reach
- Recipients
- +$3.4M
- General Payments vs PY2023
Novo Nordisk Inc reported $30,880,705.67 across all CMS Open Payments tracks (General + Research + Ownership) to 495,369 physicians and teaching hospitals in Program Year 2024 - ranking #70 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $25,466,535.69, averaging $62.34 per recipient.
How Novo Nordisk Inc's $30.9M all-tracks total breaks down
Novo Nordisk Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer novo-nordisk-inc Novo Nordisk Inc
$30.9M · #70/1,925 · 0.2% industry · PY2024
- TOT $30.9M
- RANK #70
- SHARE 0.2%
- TXN 497,147
- RCP 495,369
- CAT 8
- GEN $25.5M
- ΔGEN +$3.4M
- TOP1 0.4%
- PY 2024
Volume peers
Nearest volume peer: Chiesi USA, Inc. ($30.8M)
Novo Nordisk Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Novo Nordisk Inc's CMS-reported General Payments increased by $3.4M (+15.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVO NORDISK INCPY2023: NOVO NORDISK INCPY2024: Novo Nordisk Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $22,019,837.22
- PY2024
- $25,466,535.69
What the Data Shows for Novo Nordisk Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Novo Nordisk Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 8 general-payment categories charted below, "Food and Beverage" is the largest at $9.9M across 483,068 transactions, 38.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Novo Nordisk Inc's 8-category general-payment breakdown at $9.9M, 38.9% of the reported total.
Novo Nordisk Inc reports 8 general-payment categories - the top three are Food and Beverage (38.9%), Compensation for Services Other Than Consulting (38.6%), and Consulting Fee (15.6%). The remaining 5 categories make up 6.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Novo Nordisk Inc files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Novo Nordisk Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $9.9M | 483,068 | 38.9% |
| Compensation for Services Other Than Consulting | $9.8M | 5,182 | 38.6% |
| Consulting Fee | $4.0M | 1,100 | 15.6% |
| Travel and Lodging | $1.3M | 3,157 | 5.3% |
| Space Rental or Facility Fees | $175.2K | 116 | 0.7% |
| Grant | $119.6K | 6 | 0.5% |
| Education | $95.8K | 2,735 | 0.4% |
| Honoraria | $10.0K | 5 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $501,668.86 (2.0%) of $25,466,535.69 in this company's General Payments records across 110,660 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Novo Nordisk Inc
The five named recipients with the highest reported General Payments from this company
- 1
Sanjay Rajagopalan
$109,475.72 across 52 reported transactions
- 2
Naveed Ali Rajper
$104,100.04 across 47 reported transactions
- 3
Matthew Budoff
$99,591.91 across 38 reported transactions
- 4
Sonal Kumar
$98,394.18 across 39 reported transactions
- 5
Carolina Del Socorro Solis-Herrera
$90,107.01 across 74 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Novo Nordisk Inc ranks #70 of 1,925 by total payments (top 4% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,830 of 1,838 by HHI (bottom 1% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- 180 Medical, Inc. : $86.9K total payments, HHI 13
- Janssen Biotech, Inc. : $30.9M total payments, HHI 13
- Amphastar Pharmaceuticals, Inc. : $41.3K total payments, HHI 13
- E.R. Squibb & Sons, L.L.C. : $31.0M total payments, HHI 12
- Aspira Women's Health Inc : $74.7K total payments, HHI 12
- Corium, LLC : $1.7M total payments, HHI 11
- Novo Nordisk Inc (this company) : $25.5M total payments, HHI 9
- Beta Bionics, Inc. : $243.6K total payments, HHI 8
- Innovation Technologies Inc : $205.0K total payments, HHI 8
- Shield Therapeutics Inc : $548.7K total payments, HHI 7
- Evofem Biosciences, Inc. : $90.0K total payments, HHI 7
- Noven Therapeutics, LLC : $197.9K total payments, HHI 4
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Novo Nordisk Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Novo Nordisk Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Novo Nordisk Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Eisai Inc.
$31.1M 50,482 recipients
Compare payment profiles
Medical Device Business Services, Inc.
$31.1M 32,296 recipients
Compare payment profiles
Novavax Inc
$30.4M 104 recipients
Compare payment profiles
Janssen Biotech, Inc.
$31.5M 298,174 recipients
Compare payment profiles
Globus Medical, Inc.
$29.9M 23,188 recipients
Compare payment profiles
Put this to use
Novo Nordisk Inc ranks #70 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Novo Nordisk Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Novo Nordisk Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.